Merck (MRK)
International Stocks
Buy
Evaluates the company's acquisition strategy in biotechnology and the expansion of its drug portfolio.
Yahoo Finance23d
* Does not constitute investment advice
Yükleniyor...
Yükleniyor...
How recommendation distribution changed over time
Covered by 5 analysts
Analysts are largely in agreement
Last evaluation 23 days ago
One-directional consensus
Decreasing interest recently
Chronological view of analyst recommendations for this asset
Evaluates the company's acquisition strategy in biotechnology and the expansion of its drug portfolio.
Yahoo FinanceThe company's solid earnings, valuation, and overall market performance are examined.
CNBC TelevisionThe speaker evaluates the pharmaceutical company's strong earnings and stable performance in current market conditions. He analyzes the company's future expectations and its position in the sector.
CNBC TelevisionThe speaker examines Merck's fourth-quarter performance, noting its relatively stronger position compared to peers. The analysis includes investor sentiment regarding the pipeline improvements and the anticipated Keytruda patent expiration.
CNBC TelevisionThe speaker evaluates tactical opportunities in the healthcare sector and emphasizes the defensive characteristics of the stock added to the portfolio.
CNBC TelevisionThe speaker discusses the strategy of selling covered calls to generate additional cash flow while maintaining the position, also noting positive developments in acquisition talks.
CNBC TelevisionThe speaker examines the merger and acquisition activity specifically regarding Merck and the broader sector ahead of the upcoming JP Morgan Healthcare Conference.
CNBC TelevisionThe speaker evaluates the upgrade of the company from 'hold' to 'buy' and potential breakout scenarios ahead of the upcoming JP Morgan Healthcare Conference.
CNBC TelevisionThe speaker discusses the reasons for upgrading the stock rating to 'Outperform' and the company's long-term portfolio strategy.
CNBC TelevisionThe expert analyzes the potential reflections of the government's softer stance on drug pricing policies on company balance sheets and acquisition appetite.
CNBC TelevisionThe speaker evaluates the significant technical breakout of the stock alongside the general strengthening in the Health Care sector.
CNBC TelevisionThe speaker examines the capital movement towards healthcare giants following the decline in data center stocks.
CNBC TelevisionThe speaker analyzes the pharma giant's low valuation, strong dividend yield, and developments in the new product pipeline to replace drugs with expiring patents.
CNBC TelevisionEvaluates the company's acquisition strategy in biotechnology and the expansion of its drug portfolio.
* Does not constitute investment advice
The company's solid earnings, valuation, and overall market performance are examined.
* Does not constitute investment advice
The speaker evaluates the pharmaceutical company's strong earnings and stable performance in current market conditions. He analyzes the company's future expectations and its position in the sector.
* Does not constitute investment advice
The speaker examines Merck's fourth-quarter performance, noting its relatively stronger position compared to peers. The analysis includes investor sentiment regarding the pipeline improvements and the anticipated Keytruda patent expiration.
* Does not constitute investment advice
The speaker evaluates tactical opportunities in the healthcare sector and emphasizes the defensive characteristics of the stock added to the portfolio.
* Does not constitute investment advice
The speaker discusses the strategy of selling covered calls to generate additional cash flow while maintaining the position, also noting positive developments in acquisition talks.
* Does not constitute investment advice
The speaker examines the merger and acquisition activity specifically regarding Merck and the broader sector ahead of the upcoming JP Morgan Healthcare Conference.
* Does not constitute investment advice
The speaker evaluates the upgrade of the company from 'hold' to 'buy' and potential breakout scenarios ahead of the upcoming JP Morgan Healthcare Conference.
* Does not constitute investment advice
The speaker discusses the reasons for upgrading the stock rating to 'Outperform' and the company's long-term portfolio strategy.
* Does not constitute investment advice
The expert analyzes the potential reflections of the government's softer stance on drug pricing policies on company balance sheets and acquisition appetite.
* Does not constitute investment advice
The speaker evaluates the significant technical breakout of the stock alongside the general strengthening in the Health Care sector.
* Does not constitute investment advice
The speaker examines the capital movement towards healthcare giants following the decline in data center stocks.
* Does not constitute investment advice
The speaker analyzes the pharma giant's low valuation, strong dividend yield, and developments in the new product pipeline to replace drugs with expiring patents.
* Does not constitute investment advice